Nvidia's Rubin Chip Production on Track in Q2, but Rack-Level Cooling Issues Delaying Mass Production, UBS Says

Nvidia's (NVDA) Rubin chip and compute board production is on track in the current quarter, but rack-level cooling issues is pushing rack mass production into the September timeframe, which should be offset by robust demand for Blackwell, UBS said in a Wednesday research report.

There is potential for a new share repurchase program commitment of up to $150 billion over the next 12 months, while investors expect a larger dividend commitment in the current quarter, analysts wrote. The company is due to report fiscal Q1 results on May 20.

UBS said it expects 2027 and 2028 EPS of $14.35 and $17.07, respectively, on revenue of $607 billion and $710 billion. For 2026, the brokerage now expects revenue of $400 billion from $393 billion earlier.

The company's GTC messaging regarding system-level design implies that it continues to offer more value to clients as the competitive landscape evolves, according to UBS.

The brokerage said it reiterated its buy rating on the stock and boosted its price target to $275 per share from $245.

Price: $236.15, Change: $+10.32, Percent Change: +4.57%

Argus Lowers McDonald's Price Target to $320 From $380

McDonald's (MCD) has an average rating of overweight and mean price target of $332.47, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $275.01, Change: $-0.69, Percent Change: -0.25%

$MCD

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

(Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's (RGNX) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: $6.47, Change: $-3.57, Percent Change: -35.56%

$RGNX

Nvidia's Rubin Chip Production on Track in Q2, but Rack-Level Cooling Issues Delaying Mass Production, UBS Says

Related Articles

Argus Lowers McDonald's Price Target to $320 From $380

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

Altria Maintains Quarterly Dividend at $1.06 per Share, Payable July 10 to Holders of Record June 15